Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE) - 23/04/21
, Umar I. Malik, MD a, Rachel C. Thomas, RN b, Rishi V. Parikh, MPH b, Thida C. Tan, MPH b, Choon H. Goh, MD, MPH a, Van N. Selby, MD a, Matthew D. Solomon, MD, PhD b, c, Harshith R. Avula, MD, MPH d, Jesse K. Fitzpatrick, MD a, Jacek Skarbinski, MD b, e, Sephy Philip, RPh, PharmD f, Craig Granowitz, MD, PhD f, Deepak L. Bhatt, MD, MPH g, Alan S. Go, MD b, h, i, jRésumé |
Objective |
The MITIGATE study aims to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), compared with usual care, on laboratory-confirmed viral upper respiratory infection (URI)-related morbidity and mortality in adults with established atherosclerotic cardiovascular disease (ASCVD).
Background |
IPE is a highly purified and stable omega-3 fatty acid prescription medication that is approved for cardiovascular risk reduction in high-risk adults on statin therapy with elevated triglycerides. Preclinical data and clinical observations suggest that IPE may have pleiotropic effects including antiviral and anti-inflammatory properties that may prevent or reduce the downstream sequelae and cardiopulmonary consequences of viral URIs.
Methods |
MITIGATE is a virtual, electronic health record-based, open-label, randomized, pragmatic clinical trial enrolling ∼16,500 participants within Kaiser Permanente Northern California – a fully integrated and learning health care delivery system with 21 hospitals and >255 ambulatory clinics serving ∼4.5 million members. Adults ≥50 years with established ASCVD and no prior history of coronavirus disease 2019 (COVID-19) will be prospectively identified and pre-randomized in a 1:10 allocation ratio (∼ 1,500 IPE: ∼15,000 usual care) stratified by age and previous respiratory health status to the intervention (IPE 2 grams by mouth twice daily with meals) vs the control group (usual care) for a minimum follow-up duration of 6 months. The co-primary endpoints are moderate-to-severe laboratory-confirmed viral URI and worst clinical status due to a viral URI at any point in time.
Conclusion |
The MITIGATE study will inform clinical practice by providing evidence on the real-world clinical effectiveness of pretreatment with IPE to prevent and/or reduce the sequelae of laboratory-confirmed viral URIs in a high-risk cohort of patients with established ASCVD.
Le texte complet de cet article est disponible en PDF.Keywords : Atherosclerotic cardiovascular disease, triglycerides, icosapent ethyl, viral upper respiratory infection, coronavirus disease 2019, seasonal flu
Plan
Vol 235
P. 54-64 - mai 2021 Retour au numéro
Article précédent
- Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
- Warren H. Capell, Elliot S. Barnathan, Gregory Piazza, Alex C. Spyropoulos, Judith Hsia, Scott Bull, Concetta Lipardi, Chiara Sugarmann, Eunyoung Suh, Jaya Prakash Rao, William R. Hiatt, Marc P. Bonaca
- Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance
- StephenJ Nicholls, A Michael Lincoff, Harold E Bays, Leslie Cho, Diederick E Grobbee, John JP Kastelein, Peter Libby, Patrick M Moriarty, Jorge Plutzky, Kausik K Ray, Paul D. Thompson, William Sasiela, Denise Mason, Jaclyn McCluskey, Deborah Davey, Kathy Wolski, Steven E Nissen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?